Roche (RHHBY) is upgraded to Buy as strong 2025 growth, new drug launches, and obesity drug potential create an attractive ...
Dr. Charles M. Rudin highlighted new small cell lung cancer therapies, including T cell engagers, antibody-drug conjugates, ...
KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company developing cutting-edge, multi-mechanistic oncolytic immunotherapies, today announced a clinical trial collaboration and supply ...
Bristol Myers BMY has a robust oncology portfolio, including the blockbuster immune-oncology drugs, Opdivo, Opdivo Qvantig ...
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...
GlobalData on MSN
USPTO grants patent to Genprex’s Reqorsa gene therapy
The US Patent and Trademark Office (USPTO) has granted a patent to Genprex for the use of its Reqorsa gene therapy ...
KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company developing cutting-edge, multi-mechanistic oncolytic immunotherapies, today announced a clinical trial collaboration and supply ...
Emerging TNBC therapies include TECENTRIQ (Hoffmann-La Roche), IPI-549 (Infinity Pharmaceuticals), Leronlimab (CytoDyn), MDNA11 (Medicenna Therapeutics), VIP236 (Vincerx Pharma), and CFI-400945 ...
New Clinical Trial Site Added for Clinical Studies of Reqorsa® Gene Therapy to Treat Lung Cancer Acclaim-1 and Acclaim-3 ...
After laying off 80% of staffers this spring, Tempest Therapeutics is acquiring several CAR-T programs from Factor Bioscience ...
Akeso has a validated process in place for developing antibodies but does require US exposure to meet its lofty valuation.
New Clinical Trial Site Added for Clinical Studies of Reqorsa® Gene Therapy to Treat Lung Cancer Acclaim-1 and Acclaim-3 Clinical Trials Supported by FDA Fast Track ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback